Research graph
References from Hematological diseases-related mucormycosis: A retrospective single center study. Local targets link to admitted publications; unresolved targets remain external evidence.
The ecology of the Zygomycetes and its impact on environmental exposure
10.1111/j.1469-0691.2009.02972.x · 2009 · External reference
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
10.1016/s1473-3099(19)30312-3 · 2019 · External reference
The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports
10.1016/j.cmi.2018.07.011 · 2019 · External reference
Advances in the diagnosis and treatment of fungal infections of the CNS
10.1016/s1474-4422(18)30030-9 · 2018 · External reference
The Role of Metagenomics and Next-Generation Sequencing in Infectious Disease Diagnosis
10.1093/clinchem/hvab173 · 2021 · External reference
Mucor indicus caused disseminated infection diagnosed by metagenomic next-generation sequencing in an acute myeloid leukemia patient: A case report
10.3389/fcimb.2023.1089196 · 2023 · External reference
Global Epidemiology of Mucormycosis
10.3390/jof5010026 · 2019 · External reference
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006
10.3201/eid1509.090334 · 2009 · External reference
Epidemiology and clinical manifestations of mucormycosis
2012 · External reference
Mucormycosis in Australia: contemporary epidemiology and outcomes
10.1016/j.cmi.2016.01.005 · 2016 · External reference
Epidemiology and outcome of zygomycosis: a review of 929 reported cases
10.1086/432579 · 2005 · External reference
Mucormycosis
10.1016/j.idc.2021.03.009 · 2021 · External reference
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
10.1093/cid/ciz1008 · 2020 · External reference
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
10.1016/s1473-3099(16)00071-2 · 2016 · External reference
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
10.1086/590004 · 2008 · External reference
Nasal and cutaneous mucormycosis in two patients with lymphoma after chemotherapy and target therapy: Early detection by metagenomic next-generation sequencing
10.3389/fcimb.2022.960766 · 2022 · External reference
Comparison of metagenomic next-generation sequencing and conventional culture for the diagnostic performance in febrile patients with suspected infections
10.1186/s12879-024-09236-w · 2024 · External reference
Improving Pulmonary Infection Diagnosis with Metagenomic Next Generation Sequencing
10.3389/fcimb.2020.567615 · 2021 · External reference
High-Throughput Metagenomics for Identification of Pathogens in the Clinical Settings
10.1002/smtd.202000792 · 2021 · External reference
Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)
10.1111/j.1469-0691.2012.03908.x · 2012 · External reference
Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome
10.1007/s15010-018-1149-x · 2018 · External reference
IFN-γ Mediated Signaling Improves Fungal Clearance in Experimental Pulmonary Mucormycosis
10.1007/s11046-021-00598-2 · 2022 · External reference
The cross-talk between mucormycosis, steroids and diabetes mellitus amidst the global contagion of COVID-19
10.1080/1040841x.2022.2052795 · 2023 · External reference
Posaconazole mono- or combination therapy for treatment of murine zygomycosis
10.1128/aac.01124-08 · 2009 · External reference
Invasive mold infections following combat-related injuries
10.1093/cid/cis749 · 2012 · External reference
Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia
10.1111/j.1439-0507.2006.01299.x · 2006 · External reference
Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis
10.1128/aac.00313-13 · 2013 · External reference
Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients
10.1182/blood-2011-07-366526 · 2011 · External reference
Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation
10.1093/infdis/jis308 · 2012 · External reference
Natural and modified IL-2 for the treatment of cancer and autoimmune diseases
10.1016/j.clim.2018.11.002 · 2019 · External reference
Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes
10.1086/428503 · 2005 · External reference
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
10.1093/cid/ciw444 · 2016 · External reference
Nivolumab plus interferon-γ in the treatment of intractable mucormycosis
10.1016/s1473-3099(16)30541-2 · 2017 · External reference
The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
10.1016/s2666-5247(21)00237-8 · 2022 · External reference
Unresolved reference
2021 · External reference
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1
10.4103/ijo.ijo_1565_21 · 2021 · External reference
Coronavirus Disease 2019-Associated Mucormycosis: Risk Factors and Mechanisms of Disease
10.1093/cid/ciab726 · 2022 · External reference
Invasive Fungal Infections Associated with COVID-19
10.3390/jof9060667 · 2023 · External reference
Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro
10.1128/iai.38.1.292-297.1982 · 1982 · External reference
Update on mucormycosis pathogenesis
10.1097/qco.0000000000000008 · 2013 · External reference
Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus
10.1172/jci111395 · 1984 · External reference
Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis
10.1086/597615 · 2009 · External reference
Absence of Case of Mucormycosis (March 2020-May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit
10.1016/j.dsx.2021.06.006 · 2021 · External reference
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India
10.1016/j.dsx.2021.05.019 · 2021 · External reference
Zygomycosis in the 1990s in a tertiary-care cancer center
10.1086/313803 · 2000 · External reference
Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association
10.1111/myc.12862 · 2019 · External reference
Pathogenesis of mucormycosis
2012 · External reference
Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation
10.1148/rg.2020190156 · 2020 · External reference
Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro
10.1128/iai.38.2.487-495.1982 · 1982 · External reference
Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage
10.1128/aac.01136-07 · 2008 · External reference
Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors
10.1128/aac.01018-07 · 2008 · External reference
Mucormycosis-associated fungal infections in patients with haematologic malignancies
10.1111/j.1742-1241.2006.01145.x · 2009 · External reference
